Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1998
Business Overview: The Company develops, manufactures, and markets catheter-based technologies for less invasive medicine. The reporting period reflects significant strategic activity, including the announcement of a definitive agreement to acquire Schneider Worldwide for approximately $2.1 billion and the acquisition of CardioGene Therapeutics, Inc.
Key Financial Metrics
| Metric (in thousands) | Q2 1998 | Q2 1997 | 6 Months 1998 | 6 Months 1997 |
|---|---|---|---|---|
| Net Sales | $505,731 | $473,749 | $975,736 | $904,280 |
| Gross Profit | $354,501 | $342,294 | $684,547 | $651,768 |
| Gross Margin % | 70.1% | 72.3% | 70.2% | 72.1% |
| Operating Income | $126,952 | ($18,972) | $233,747 | $93,943 |
| Net Income | $78,736 | ($26,896) | $145,635 | $48,540 |
| Diluted EPS | $0.39 | ($0.14) | $0.73 | $0.24 |
| Cash & Equivalents (End of Period) | $148,588 | $54,141 | $148,588 | $54,141 |
| Working Capital | $896,482 | $256,010 | $896,482 | $256,010 |
| Total Debt (Current + Long-term) | $578,319 | $493,533 | $578,319 | $493,533 |
Note: Debt figures include borrowings due within one year and long-term debt. Working capital is calculated as Total Current Assets minus Total Current Liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% in Q2 1998 and 8% for the six-month period compared to 1997. Excluding foreign exchange impacts, sales growth was approximately 11% for Q2 and 12% for the six-month period.
- Profitability Turnaround: The Company reported a net income of $79 million in Q2 1998, a significant improvement from a net loss of $27 million in Q2 1997. This turnaround is largely driven by a $20 million reversal of previously accrued merger-related charges in 1998, compared to $146 million in merger charges recorded in 1997.
- Margin Compression: Gross margin decreased from 72.3% to 70.1% in Q2 1998. Management attributes this to inventory write-downs, declining average selling prices due to healthcare cost pressures, higher manufacturing costs, and unfavorable foreign exchange rates.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose to 35.9% of sales in Q2 1998 from 33.1% in 1997, driven by costs for a new global information system and expansion of direct sales in emerging markets. R&D expenses also increased to 9.6% of sales.
- Liquidity Improvement: Cash and short-term investments increased to $156 million from $80 million at year-end 1997. This was facilitated by the issuance of $500 million in debt securities in March 1998, which was used to repay commercial paper.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Acquisition Financing: The Company has secured a commitment to finance the $2.1 billion Schneider acquisition. It expects to raise permanent financing through commercial paper, convertible securities, and equity.
- Capital Expenditures: The Company anticipates incurring an additional $80 million to $90 million in capital expenditures for the remainder of 1998, including manufacturing expansion and completion of a global information system.
- Inventory Management: Inventory levels are expected to peak in 1998 due to stocking for the NIR stent launch in the U.S. and Japan. The Company expects levels to decline as the new global supply chain system becomes operational.
- Tax Rate: The effective tax rate improved to 32% in the first half of 1998 but may increase modestly in the second half.
Risks and Contingencies
- Patent Litigation: The Company is involved in numerous patent infringement suits, including significant actions with Advanced Cardiovascular Systems (ACS), C.R. Bard, Cook Inc., Cordis, and Johnson & Johnson. An adverse outcome could materially affect financial condition. Notably, a jury previously awarded C.R. Bard $10.8 million in damages, though the Company intends to appeal.
- Market Pressures: Continued consolidation among healthcare providers and managed care trends may pressure selling prices and gross margins.
- Foreign Exchange: International sales (approx. 43% of total) are subject to currency fluctuations, which negatively impacted results in the first half of 1998 due to a strengthening U.S. dollar.
Investor Verification Checklist
- Merger Charge Reversal: Verify the sustainability of earnings by analyzing the $20 million reversal of merger-related charges, which significantly boosted Q2 net income.
- Schneider Acquisition: Confirm the status of the $2.1 billion acquisition of Schneider Worldwide and the terms of the permanent financing to be secured.
- Inventory Levels: Monitor inventory trends closely, as levels are expected to peak in 1998; assess the risk of future write-downs if the NIR stent launch or supply chain optimization faces delays.
- Legal Exposure: Review the status of pending patent litigation, particularly the C.R. Bard appeal and the multiple suits involving the NIR stent, to assess potential liability.
- Debt Structure: Analyze the impact of the new $500 million debt issuance on future interest expenses and liquidity, especially in the context of the pending acquisition financing.